Aortic Valve Insufficiency

GE HealthCare; ESC25; AI cardiology; diagnostic accuracy; ViewPoint EchoPilot; CardIQ Suite; Revolution Vibe CT; molecular imaging; workflow automation; electrophysiology; cardiac imaging; FDA authorization

Personalizing Metabolic Care with Digital Twins: Recent Developments

3 weeks ago talkbio0Tagged Administration occupational activities, Aortic Valve Insufficiency, Biological Markers, Diabetes, digital twins, Glucagon-Like Peptide 1, Health care facility, metabolic health, Obesity, Precision Medicine, real-time guidance, Reversal, Twin Health

digital twins; metabolic health; AI healthcare; personalized medicine; biomarkers; diabetes management; obesity reversal; real-time guidance; GLP-1; Twin Health

Recent Advances: AI in Life Sciences—Reimagining Teams, Technology, and Partnerships

3 weeks ago talkbio0Tagged Aortic Valve Insufficiency, Biological Science Disciplines, Data Integration, Drug Discovery, Generative AI, language models, Precision Medicine, strategic partnerships, team transformation, technology innovation

AI in life sciences; generative AI; large language models; team transformation; technology innovation; strategic partnerships; drug discovery; personalized medicine; data integration

Who Is Making AI Work in Drug R&D in 2025?

3 weeks ago talkbio0Tagged Advice, Aortic Valve Insufficiency, Big Pharma, biopharma startups, Clinical Trials, Drug Development, Efficiency, Precision Medicine, United States Food and Drug Administration

AI drug discovery; Big Pharma; biopharma startups; clinical trials; FDA guidance; personalized medicine; drug development efficiency

VantAI and Halda Strike $1B+ AI-Driven Partnership on ‘Hold-and-Kill’ Drugs

4 weeks ago talkbio0Tagged Aortic Valve Insufficiency, cellular targeting, Chimera organism, Drug Discovery, Halda Therapeutics, hold-and-kill, Immunology, Induce (action), Neoplasms, Proximity, RIPTAC, target-effector pairs, VantAI

VantAI; Halda Therapeutics; RIPTAC drugs; hold-and-kill; AI drug discovery; target-effector pairs; oncology; immunology; regulated induced proximity targeting chimeras; $1 billion deal

Eli Lilly and Superluminal Ink $1.3B Pact Targeting GPCRs in Obesity, Cardiometabolic Diseases

1 month ago talkbio0Tagged Aortic Valve Insufficiency, cardiometabolic diseases, Eli, Eli Lilly, equity, GPCRs, Investments, MC4R, MC4R protein, human, milestones, Obesity, Partnership, Superluminal Medicines

Eli Lilly; Superluminal Medicines; GPCRs; obesity drugs; cardiometabolic diseases; AI drug discovery; MC4R; partnership; milestones; equity investment

AI, Media and the Evolution of Omnichannel in Healthcare Marketing — Ray Rosti on Episode 3 of The Next Marketing with HJ

1 month ago talkbio0Tagged Aortic Valve Insufficiency, Automation, Biomechanical compliance, Communications Media, connected journeys, content intelligence, Doceree, Engaged to be married, Health Care Market, Hereditary Coproporphyria, Klick Media, Measurement, omnichannel, Optimization, personalization, Pharma, Privacy, Region of interest:Presence or Identity:Point in time:*:Nominal

AI in healthcare marketing; omnichannel; first‑party data; content intelligence; media optimization; privacy and compliance; measurement and ROI; pharma marketing; Klick Media; Doceree; HCP engagement; personalization; automation; connected journeys